Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INCY 
Incyte Corporation (INCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: INCY (3-star) is a STRONG-BUY. BUY since 114 days. Simulated Profits (44.30%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
27 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $89.1
1 Year Target Price $89.1
| 8 | Strong Buy |
| 3 | Buy |
| 15 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.26% | Avg. Invested days 46 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 18.35B USD | Price to earnings Ratio 15.84 | 1Y Target Price 89.1 |
Price to earnings Ratio 15.84 | 1Y Target Price 89.1 | ||
Volume (30-day avg) 27 | Beta 0.74 | 52 Weeks Range 53.56 - 95.10 | Updated Date 11/1/2025 |
52 Weeks Range 53.56 - 95.10 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-28 | When Before Market | Estimate 1.64 | Actual 2.26 |
Profitability
Profit Margin 24.7% | Operating Margin (TTM) 31.63% |
Management Effectiveness
Return on Assets (TTM) 13.54% | Return on Equity (TTM) 30.39% |
Valuation
Trailing PE 15.84 | Forward PE 12.5 | Enterprise Value 14469095790 | Price to Sales(TTM) 3.81 |
Enterprise Value 14469095790 | Price to Sales(TTM) 3.81 | ||
Enterprise Value to Revenue 3.16 | Enterprise Value to EBITDA 10.67 | Shares Outstanding 196322703 | Shares Floating 163640863 |
Shares Outstanding 196322703 | Shares Floating 163640863 | ||
Percent Insiders 2.02 | Percent Institutions 104.1 |
Upturn AI SWOT
Incyte Corporation
Company Overview
History and Background
Incyte Corporation was founded in 2002 and is headquartered in Wilmington, Delaware. It initially focused on genomics and drug discovery technology. The company has evolved into a biopharmaceutical company focused on discovering, developing, and commercializing proprietary therapeutics.
Core Business Areas
- Oncology: Incyte's oncology segment focuses on developing and commercializing treatments for various cancers. This includes JAK inhibitors and other targeted therapies.
- Inflammation and Autoimmunity: This segment focuses on developing treatments for inflammatory and autoimmune diseases. This includes topical treatments and other therapies.
Leadership and Structure
Herve Hoppenot serves as the Chief Executive Officer. The company has a typical corporate structure with various departments reporting to the CEO and executive team.
Top Products and Market Share
Key Offerings
- Jakafi (ruxolitinib): Jakafi is a JAK1/JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and acute graft-versus-host disease. It is a major revenue driver for Incyte. Novartis markets ruxolitinib outside the United States as Jakavi. Revenue data as of 2023: ~$2.4 billion globally. Competitors: Constellation Pharmaceuticals (pelabresib) for myelofibrosis.
- Opzelura (ruxolitinib cream): Opzelura is a topical formulation of ruxolitinib approved for atopic dermatitis and vitiligo. Market share is growing as it is a newer product. Competitors: Corticosteroids and other topical treatments.
- Pemazyre (pemigatinib): Pemazyre is a selective fibroblast growth factor receptor (FGFR) inhibitor approved for cholangiocarcinoma (bile duct cancer) with FGFR2 fusions or rearrangements. Estimated revenue of 99.58 million (2023). Competitors: Other targeted therapies for cholangiocarcinoma, such as chemotherapy.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Key trends include the development of targeted therapies, personalized medicine, and innovative drug delivery systems. The industry is also subject to regulatory scrutiny and pricing pressures.
Positioning
Incyte is positioned as an innovative biopharmaceutical company focused on developing and commercializing novel therapies for unmet medical needs. Its competitive advantages include its expertise in kinase inhibitors and its established commercial infrastructure for hematology-oncology products.
Total Addressable Market (TAM)
The total addressable market for Incyte's products is estimated to be in the billions of dollars, considering the prevalence of the diseases they target. Incyte is strategically positioned to capture a significant portion of this TAM through its strong portfolio and ongoing research and development efforts.
Upturn SWOT Analysis
Strengths
- Strong portfolio of approved products
- Expertise in kinase inhibitors
- Established commercial infrastructure
- Robust pipeline of development candidates
- Partnerships with major pharmaceutical companies
Weaknesses
- Reliance on key products like Jakafi
- Competition from other pharmaceutical companies
- Exposure to regulatory risks
- Need to diversify product portfolio
Opportunities
- Expansion into new therapeutic areas
- Development of novel drug candidates
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Label expansion for existing products
Threats
- Patent expirations
- Generic competition
- Pricing pressures
- Clinical trial failures
- Regulatory changes
Competitors and Market Share
Key Competitors
- NVS
- BMY
- MRK
Competitive Landscape
Incyte faces competition from other large pharmaceutical companies in the oncology and inflammation/autoimmunity markets. Its competitive advantages include its expertise in kinase inhibitors, its established commercial infrastructure, and its robust pipeline of development candidates.
Major Acquisitions
Villaris Therapeutics
- Year: 2022
- Acquisition Price (USD millions): 143
- Strategic Rationale: Acquired Villaris for their novel anti-IL-15 mAb program to treat vitiligo and other autoimmune diseases. Enhances Incyte's portfolio in dermatology.
Growth Trajectory and Initiatives
Historical Growth: Incyte has experienced significant growth in revenue and profitability over the past decade, driven by the success of Jakafi and the launch of other products.
Future Projections: Analysts project continued growth for Incyte, driven by sales of existing products and the potential approval of new drug candidates. Revenue is expected to increase in the mid-single digits annually.
Recent Initiatives: Recent initiatives include expanding the label for Opzelura, advancing clinical trials for new drug candidates, and pursuing strategic acquisitions and partnerships.
Summary
Incyte is a biopharmaceutical company with a strong portfolio of approved products and a robust pipeline. Jakafi remains a key revenue driver, and the company is expanding into new therapeutic areas. While facing competition and regulatory risks, Incyte is positioned for continued growth through strategic initiatives and ongoing research and development. The company needs to focus on diversifying its revenue streams to reduce reliance on Jakafi.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Incyte Corporation Investor Relations, SEC Filings, Analyst Reports, Company Press Releases
Disclaimers:
This analysis is based on publicly available information and represents a general overview of Incyte Corporation. It is not intended as financial advice, and investors should conduct their own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incyte Corporation
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 1993-11-04 | Advisor to CEO & Director Mr. Herve Hoppenot | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2617 | Website https://www.incyte.com |
Full time employees 2617 | Website https://www.incyte.com | ||
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.